ICCM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ICCM is not a strong buy right now for a Beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term technical improvement, but the overall trend is still bearish, there are no strong proprietary buy signals, no recent news catalyst, and the latest quarter remains unprofitable. For an impatient buyer, this is not a clear entry. The best call is hold and wait for stronger confirmation.
ICCM is trading pre-market at 0.2724, which is just above the key support area near S1 at 0.266 and below the pivot at 0.316. Momentum is mixed: the MACD histogram is positive and expanding, which suggests short-term improvement, but the RSI_6 at 35.2 is still neutral and not showing strong buying pressure. The moving average structure is bearish with SMA_200 > SMA_20 > SMA_5, indicating the broader trend remains weak. Overall, the chart shows a possible bounce area, but not a confirmed uptrend.
Revenue in 2025/Q4 increased 46.17% year over year, showing strong top-line growth. The MACD is improving, and the stock trend model suggests a positive near-term probability of 0.47% next day, 5.17% next week, and 12.45% next month. The stock is also trading close to support, which may attract short-term dip buyers.
Gross margin also declined slightly year over year. There is no valuation data, no recent congress trading data, and no recent purchases or sales by influential figures to support a bullish case.
In 2025/Q4, Icecure Medical reported revenue of 1.279 million, up 46.17% year over year, which is a positive growth signal. However, profitability remains weak: net income was -4.246 million, EPS was -0.06, and gross margin fell to 46.91%. The latest quarter shows improving sales but no turnaround in earnings yet.
No analyst rating or price target change data was provided. Based on the available information, Wall Street pros and cons lean cautious: the pro side is revenue growth and potential for a technical bounce, while the con side is ongoing losses, bearish moving averages, and no fresh catalyst.
